Wordt geladen...
Decade in review: a new era for RET-rearranged lung cancers
Targeted therapy has become the standard of care for non-small cell lung cancers with a range of targetable alterations, including ALK and ROS1 kinase fusions. RET fusions drive the oncogenesis of 1–2% of NSCLCs and represent a substantial global burden of disease. Although these fusions were first...
Bewaard in:
| Gepubliceerd in: | Transl Lung Cancer Res |
|---|---|
| Hoofdauteurs: | , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
AME Publishing Company
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7815364/ https://ncbi.nlm.nih.gov/pubmed/33489819 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr-20-346 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|